IL318945A - Combination therapies for treatment of cirrhosis with portal hypertension - Google Patents
Combination therapies for treatment of cirrhosis with portal hypertensionInfo
- Publication number
- IL318945A IL318945A IL318945A IL31894525A IL318945A IL 318945 A IL318945 A IL 318945A IL 318945 A IL318945 A IL 318945A IL 31894525 A IL31894525 A IL 31894525A IL 318945 A IL318945 A IL 318945A
- Authority
- IL
- Israel
- Prior art keywords
- cirrhosis
- treatment
- combination therapies
- portal hypertension
- portal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263371228P | 2022-08-12 | 2022-08-12 | |
| PCT/EP2023/072278 WO2024033519A1 (en) | 2022-08-12 | 2023-08-11 | Combination therapies for treatment of cirrhosis with portal hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL318945A true IL318945A (en) | 2025-04-01 |
Family
ID=87760695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318945A IL318945A (en) | 2022-08-12 | 2023-08-11 | Combination therapies for treatment of cirrhosis with portal hypertension |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240058331A1 (en) |
| EP (1) | EP4568673A1 (en) |
| JP (1) | JP2025526746A (en) |
| KR (1) | KR20250044929A (en) |
| CN (1) | CN119855594A (en) |
| AR (1) | AR130179A1 (en) |
| AU (1) | AU2023321653A1 (en) |
| CA (1) | CA3264757A1 (en) |
| CL (1) | CL2025000385A1 (en) |
| DO (1) | DOP2025000024A (en) |
| IL (1) | IL318945A (en) |
| MX (1) | MX2025001713A (en) |
| TW (1) | TW202423417A (en) |
| UY (1) | UY40392A (en) |
| WO (1) | WO2024033519A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260097057A1 (en) * | 2024-10-09 | 2026-04-09 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease and liver fibrosis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA58494C2 (en) | 1995-06-07 | 2003-08-15 | Зенека Лімітед | N-heteroaryl-pyridinesulfonamide derivatives, pharmaceutical composition, process for preparing thereof and method for endothelin influence counteraction |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| WO2020081766A1 (en) * | 2018-10-18 | 2020-04-23 | Avolynt | Use of sglt2 inhibitors to treat primary sclerosing cholangitis |
| EP3639827A1 (en) * | 2018-10-19 | 2020-04-22 | Noorik Biopharmaceuticals AG | Use of ambrisentan for the treatment of portal hypertension and cirrhosis |
| WO2021014351A1 (en) * | 2019-07-23 | 2021-01-28 | Novartis Ag | Treatment comprising sglt inhibitors, e.g. sglt 1/2 inhibitors |
| PH12023550025A1 (en) * | 2020-07-10 | 2024-03-11 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease |
-
2023
- 2023-08-11 AR ARP230102120A patent/AR130179A1/en unknown
- 2023-08-11 JP JP2025507522A patent/JP2025526746A/en active Pending
- 2023-08-11 EP EP23757862.0A patent/EP4568673A1/en active Pending
- 2023-08-11 AU AU2023321653A patent/AU2023321653A1/en active Pending
- 2023-08-11 IL IL318945A patent/IL318945A/en unknown
- 2023-08-11 CN CN202380059072.0A patent/CN119855594A/en active Pending
- 2023-08-11 US US18/448,559 patent/US20240058331A1/en active Pending
- 2023-08-11 TW TW112130316A patent/TW202423417A/en unknown
- 2023-08-11 CA CA3264757A patent/CA3264757A1/en active Pending
- 2023-08-11 KR KR1020257008116A patent/KR20250044929A/en active Pending
- 2023-08-11 WO PCT/EP2023/072278 patent/WO2024033519A1/en not_active Ceased
- 2023-08-14 UY UY0001040392A patent/UY40392A/en not_active Application Discontinuation
-
2025
- 2025-02-07 DO DO2025000024A patent/DOP2025000024A/en unknown
- 2025-02-10 CL CL2025000385A patent/CL2025000385A1/en unknown
- 2025-02-11 MX MX2025001713A patent/MX2025001713A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025001713A (en) | 2025-04-02 |
| US20240058331A1 (en) | 2024-02-22 |
| AU2023321653A1 (en) | 2025-03-27 |
| CL2025000385A1 (en) | 2025-07-04 |
| EP4568673A1 (en) | 2025-06-18 |
| JP2025526746A (en) | 2025-08-15 |
| KR20250044929A (en) | 2025-04-01 |
| WO2024033519A1 (en) | 2024-02-15 |
| UY40392A (en) | 2024-02-15 |
| DOP2025000024A (en) | 2025-05-30 |
| CA3264757A1 (en) | 2024-02-15 |
| AR130179A1 (en) | 2024-11-13 |
| CN119855594A (en) | 2025-04-18 |
| TW202423417A (en) | 2024-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL325744A (en) | Combination therapies for the treatment of cancer | |
| IL316706A (en) | Macrocycle compounds for the treatment of cancer | |
| IL316867A (en) | Macrocyclic inhibitors of kras for the treatment of cancer | |
| IL288522A (en) | Egfr inhibitor for the treatment of cancer | |
| SI4065585T1 (en) | Substituted macrocyclic compounds and related methods of treatment | |
| IL304595A (en) | Bicyclic tetrahydroazepine derivatives for the treatment of cancer | |
| IL315892A (en) | 5-meo-dtm for the treatment of bipolar disorder | |
| IL285999A (en) | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction | |
| IL318512A (en) | Methods for the treatment of hypertension via transcranial-focused-ultrasound | |
| IL307465A (en) | Combination therapies for the treatment of cancer | |
| IL284480A (en) | Composition and methods for treatment of primary ciliary dyskinesia | |
| IL316829A (en) | Menin-mll inhibitors for the treatment of cancer | |
| GB2605996B (en) | Enhancement of treatment with immunotherapeutic agents | |
| IL276817A (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer | |
| IL318209A (en) | Therapeutic compounds and methods | |
| IL315503A (en) | Methods of treatment | |
| CA3264757A1 (en) | Combination therapies for treatment of cirrhosis with portal hypertension | |
| IL320711A (en) | Methods of treatment | |
| IL289201A (en) | Compounds for treatment of cancer | |
| IL287213A (en) | Methods for treatment of subjects with psoriatic arthritis | |
| IL305780A (en) | Methods for the treatment of cancer | |
| GB202201824D0 (en) | Methods of treatment | |
| IL299210A (en) | Combination verapamil and mometasone therapy for the treatment of chronic rhinosinusitis | |
| IL319193A (en) | Combination therapies using prmt5 inhibitors and bcl-2 family inhibitors for the treatment of cancer | |
| GB202201825D0 (en) | Methods of treatment |